BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/25/2018 3:44:36 AM | Browse: 737 | Download: 851
 |
Received |
|
2018-07-16 04:51 |
|
Peer-Review Started |
|
2018-07-16 06:40 |
|
To Make the First Decision |
|
2018-07-25 01:24 |
|
Return for Revision |
|
2018-07-31 06:38 |
|
Revised |
|
2018-08-02 11:51 |
|
Second Decision |
|
2018-08-20 06:57 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2018-08-24 09:09 |
|
Articles in Press |
|
2018-08-24 09:09 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2018-09-20 08:00 |
|
Publish the Manuscript Online |
|
2018-09-25 03:44 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Editorial |
| Article Title |
Interleukin 12/interleukin 23 pathway: Biological basis and therapeutic effect in patients with Crohn's disease
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Ioanna Aggeletopoulou, Stelios F Assimakopoulos, Christos Konstantakis and Christos Triantos |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Christos Triantos, PhD, Assistant Professor, Chief Doctor, Senior Scientist, Department of Gastroenterology, University Hospital of Patras, D. Stamatopoulou 4, Patras 26504, Greece. chtriantos@upatras.gr |
| Key Words |
Crohn’s disease; Interleukin 12; Interleukin 23; Monoclonal antibodies; Ustekinumab; Biological agents; Interleukin 12/interleukin 23 blockade |
| Core Tip |
The therapeutic management of Crohn’s disease patients not responding to treatment with anti-tumor necrosis factor agents remains a clinical challenge. Recently, there has been increased evidence regarding the development of new drugs with alternative mechanisms of action. Interleukin (IL)-12 and IL-23 are important cytokines which are involved in the adaptive immune responses and their common pathway has been found to play a determinant role in the induction of inflammation. Clinical trials have assessed the therapeutic effect of an IL-12/IL-23 inhibitor (ustekinumab), demonstrating rapid clinical effect with a safety profile. Further studies are needed to elucidate its potential role as first-line therapy in Crohn’s disease. |
| Publish Date |
2018-09-25 03:44 |
| Citation |
Aggeletopoulou I, Assimakopoulos SF, Konstantakis C, Triantos C. Interleukin 12/interleukin 23 pathway: Biological basis and therapeutic effect in patients with Crohn's disease. World J Gastroenterol 2018; 24(36): 4093-4103 |
| URL |
http://www.wjgnet.com/1007-9327/full/v24/i36/4093.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v24.i36.4093 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
